With emerging results from the Stampede and Latitude studies, abiraterone has taken the forefront in the management of metastatic prostate cancer while researchers try to identify the ideal timing for administration. It is a potent inhibitor of CYP17 which results in androgen suppression in the testes, adrenal gland and prostate cancer cells. This is a retrospective study of 161 patients who received abiraterone. All had received prior hormone treatment, 86% received secondary hormone treatment and 33% prior chemotherapy. Lower prostate specific antigen (PSA) at abiraterone administration, longer primary androgen deprivation therapy (ADT) duration, no prior ketoconazole or chemotherapy and longer chemotherapy duration were all associated with a longer duration on abiraterone. Patients who had received >12 months of primary ADT were on abiraterone for 13 months (vs. 9 months if <12 months primary ADT). This paper adds to our understanding of the clinical predictors of response in castrate-resistant prostate cancer and could be used to try and establish the role of abiraterone in patients newly diagnosed with metastatic prostate cancer.